When you use our sites, PAREXEL will assign cookie files (“Cookies”) to you, which are a small amount of information we send to your web browser. Cookies enable the computers operating our websites to differentiate between visitors and to track the patterns of activities engaged in by different visitors. By clicking the Continue Browsing button or continuing to use this site, you agree to accept the PAREXEL Privacy Policy and all Cookies deployed on this site. You may choose to continue browsing with cookies, or leave the site.

Three drug development habits to mitigate commercial risk

In today’s cost-constrained healthcare markets, winning payer reimbursement for newly approved products has become increasingly challenging. And even if a drug wins reimbursement, there are no guarantees it will succeed in the market.

However promising a product might appear, if you do not have the right evidence early on (or if you fail to recognize that the data you do have are no longer relevant to key stakeholders), risks may actually be rising as market launch nears.

Commercial risk is so multifaceted that developers need a multifaceted strategy to cope with it, incorporating evidence generation, gated reviews and market analysis. While this will require more work, the return on the investment is high.

Previous Flipbook

How to Build a Sturdy Global Value Platform for Success in a Value-based World

Read this article to find out how PAREXEL can help you with your product value story!

Next Flipbook

Dynamic Reimbursement Working In Practice? Cancer Drugs Fund Reforms In The UK